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CMFRI develops anti-obesity medicine from marine organism 
Kochi-headquartered Central Marine Fisheries Research Institute (CMFRI) has developed an 
anti-obesity nutraceutical from seaweeds, the institute said on Wednesday. 
Kerala Governor Justice P Sathasivam will release the product during the CMFRI Platinum 
Jubilee celebrations inaugural function on Saturday, it said in a statement. 
CMFRI scientists prepared the product named Cadalmin
TM 
Antihypercholesterolemic extract 
(Cadalmin
TM
 ACe) from seaweeds which are commonly available in the Indian coastal waters 
and are known for their extraordinary medicinal properties.
 
Kajal Chakraborty, Senior Scientist in Marine Biotechnology Division of CMFRI, who 
developed the product, said Cadalmin
TM
 Antihypercholesterolemic extract can be administered 
to regulate clinical indicators leading to dyslipidemia or obesity, total adipose tissue and 
visceral fat, triglycerides besides cholesterol. 
"The product contains 100 per cent natural marine bioactive ingredients from selected seaweeds 
by a patented technology, and would be made available in 400 mg capsules," he said. 
The nutraceutical does not have any side effects as established by detailed preclinical trials. 
"Cadalmin
TM
  Antihypercholesterolemic extract is the only product made from 100 per cent 
natural marine bioactive ingredients from seaweeds as a natural remedy of obesity," said 
Chakraborty. 
P. Vijayagopal, Head, Marine Biotechnology Division, said the active ingredients in the 
product would be packed in plant based capsules to meet the dietary needs of the large 
vegetarian population in India and abroad. 
Cadalmin
TM
 Antihypercholesterolemic extract is the fourth in the series of the nutraceutical 
products developed by the CMFRI. 
Two anti-arthritic and one anti-diabetic nutraceutical products are the other three products 
developed by the institute in the past. All these technologies have been commercialised through 
pharmaceutical companies. 
According to CMFRI Director A. Gopalakrishnan, the institute is in the process of developing 
more health products from the underutilised seaweeds. 
"CMFRI is also in the process of standardising and promoting seaweed farming all along the 
Indian coasts as a livelihood option for the coastal communities. This is expected to compensate 
for the dip in income for the fishermen during lean seasons," said Gopalakrishnan. 
